StemSynergy Therapeutics
Monday, June 03, 2024
Company Presentation
![Oncology](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/BIO-track-icon_Oncology_MTC.png)
Company Presentation Theater 4
StemSynergy Therapeutics (SSTI) is a biotechnology company focused on discovering drugs that target biomolecules and cellular processes fundamental to cancer. We target the cancer stem/initiating cell (CSC) populations, with the overall aim of eliminating tumor growth. We have breakthrough technologies in modulating CSC pathways, primarily Wnt, Notch, and Myc signaling. With a multi-pronged scientific approach and a number of agents targeting these pathways, SSTI is well positioned to address critical unmet needs in cancer treatment.
![StemSynergy Therapeutics](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1823908-1-JPG.png)
Company Website:
https://stemsynergy.com
Lead Product in Development:
Small molecules targeting Wnt, Notch, and Myc signaling pathways.
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Company HQ City
Miami
Company HQ State
Florida
Company HQ Country
United States
CEO/Top Company Official
Dr. Anthony Capobianco
Development Phase of Primary Product
Pre-Clinical
Primary Speaker